Akero Therapeutics rises on positive data from fatty liver therapy study

Akero Therapeutics

05/06/2023 16:51

** Shares of drug developer Akero Therapeutics Inc  AKRO.O 
rise 5.7% to $49.41  
    ** AKRO says its experimental therapy reduced liver fat by
65% in certain patients with a type of fatty liver disease
called nonalcoholic steatohepatitis (NASH) 
    ** The drug, efruxifermin, is being tested as a potential
therapy for patients with diabetes due to NASH, who are already
being treated with a diabetes treatment belonging to a class of
drugs known as GLP-1 - Co
    ** The patients treated with efruxifermin also showed
statistically significant improvements in liver enzymes and
non-invasive markers of liver scarring - AKRO
    ** Akero plans to begin two late-stage studies of the
therapy later this year
    ** Including session's move, stock down ~11.46% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))